Cartesian Therapeutics (RNAC) Assets Average (2016 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Assets Average data on file, last reported at $292.4 million in Q1 2026.

• Assets Average for Q1 2026 came in at $292.4 million, down 30.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $292.4 million (down 30.72% YoY), and the FY2025 annual result was $365.7 million, down 1.17% from the prior year.
• Assets Average retreated to $292.4 million in Q1 2026 per RNAC's latest filing, from $334.5 million in the prior quarter.
• Over five years, Assets Average peaked at $445.2 million in Q4 2024 and troughed at $122.8 million in Q3 2023.
• A 5-year average of $272.9 million and a median of $292.4 million in 2026 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average tumbled 32.97% in 2023, then jumped 227.06% in 2024.
• A 5-year view of Assets Average shows it stood at $172.1 million in 2022, then grew by 19.45% to $205.5 million in 2023, then jumped by 116.58% to $445.2 million in 2024, then decreased by 24.85% to $334.5 million in 2025, then declined by 12.6% to $292.4 million in 2026.
• Business Quant data shows RNAC's Assets Average at $292.4 million in Q1 2026, $334.5 million in Q4 2025, and $380.8 million in Q3 2025.